OKYO Pharma Ltd has announced its participation in the upcoming 2026 Jefferies Global Healthcare Conference, which will take place in London from November 16 to 19, 2026. This event is significant for the company as it provides an opportunity to showcase its innovative therapies aimed at treating neuropathic corneal pain and other anterior segment eye diseases.

As a clinical-stage biopharmaceutical firm, OKYO Pharma is focused on developing investigational therapies that address critical needs in eye care. The conference will allow the company's leadership team to engage in one-on-one meetings with investors, potentially enhancing its visibility and investor relations within the competitive landscape of the biopharmaceutical industry.

Background

OKYO Pharma Ltd, listed on the Nasdaq under the ticker OKYO, operates within the biological products sector (SIC: 2836). The company is based in London, UK, and is recognized for its commitment to developing therapies for neuropathic corneal pain (NCP) and anterior segment eye diseases. Recent filings indicate that the company is actively engaging with investors and stakeholders to further its mission.

What the Filing Says

The filing dated November 12, 2026, states: "OKYO Pharma Limited... announced that it will participate at the 2026 Jefferies Global Healthcare Conference in London, United Kingdom taking place from November 16–19, 2026." It also mentions that the leadership team will be available for one-on-one investor meetings throughout the conference.

Impact

The participation of OKYO Pharma at this prestigious conference is expected to positively influence its interactions with investors and enhance its profile in the biopharmaceutical sector. This could lead to increased interest from potential investors and partners, thereby supporting the company's growth and development initiatives.

What's Next

The filing does not specify any further actions or developments following the conference participation.